A cross‐sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV‐1 in tenofovir disoproxil fumarate‐based pre‐exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa

Documenti analoghi

• Synthesis and characterization of tenofovir disoproxil fumarate loaded nanoparticles for HIV‐1 treatment
  di: Oluwafemi Samuel Obisesan, et al.
  Pubblicazione: (2024)
• High Burden of Symptomatic and Asymptomatic Sexually Transmitted Infections in a Routine Decentralised HIV Care Setting in Eswatini: A Cross‐Sectional Study
  di: Bernhard Kerschberger, et al.
  Pubblicazione: (2025)
• Integrating HIV and primary healthcare for key populations: community‐led models from Vietnam, Nigeria and Eswatini
  di: Megan Coleman, et al.
  Pubblicazione: (2025)
• Cluster headache‐like symptoms after initiation of tenofovir disoproxil fumarate and emtricitabine‐containing regimens for post‐ HIV exposure prophylaxis
  di: Alberto Foncillas, et al.
  Pubblicazione: (2024)
• Advancing the Study of Circular Entrepreneurship: Insights and Concepts From the European Battery Industry
  di: Riccardo Losa, et al.
  Pubblicazione: (2026)